MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Voyager Therapeutics Inc

Fechado

3.41 1.19

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.27

Máximo

3.51

Indicadores-chave

By Trading Economics

Rendimento

-25M

-34M

Vendas

-18M

6.3M

P/E

Médio do Setor

6.415

63.778

EPS

-0.59

Margem de lucro

-549.331

Funcionários

172

EBITDA

-25M

-37M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+343.7% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-31M

202M

Abertura anterior

2.22

Fecho anterior

3.41

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Voyager Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de out. de 2024, 21:31 UTC

Principais Notícias

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

Comparação entre Pares

Variação de preço

Voyager Therapeutics Inc Previsão

Preço-alvo

By TipRanks

343.7% parte superior

Previsão para 12 meses

Média 15.13 USD  343.7%

Máximo 30 USD

Mínimo 9 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Voyager Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

10

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.26 / 3.74Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.